spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  major depressive disorder 

 HSMN NewsFeed - 1 May 2024
MagVenture Announces Collaboration with Magnus Medical to Bring the SAINT(R) Neuromodulation System to Market
Devices Neurology
 HSMN NewsFeed - 21 Mar 2023
U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD
Devices Neurology FDA
 HSMN NewsFeed - 23 Dec 2021
Healis Therapeutics announces mission to deliver new class of neuromuscular treatments in psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2021
MindMed Appoints Robert Barrow as Chief Executive Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jun 2021
MindMed Announces Chief Executive Officer Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 May 2021
Eliem Therapeutics Announces $60 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 28 Apr 2021
MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms
Devices Neurology Regulatory
 HSMN NewsFeed - 6 Apr 2021
Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc.
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 17 Mar 2021
MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation
Devices Neurology Product Launch
 HSMN NewsFeed - 28 Sep 2020
AbbVie Receives Orphan Drug and Fast Track Designations from the U.S. Food and Drug Administration for Elezanumab, an Investigational Monoclonal Antibody RGMa Inhibitor, for the Treatment of Spinal Cord Injury
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 2 Sep 2020
Letter from Seneca Biopharma's Executive Chairman
Biopharmaceuticals
 HSMN NewsFeed - 11 Aug 2020
MagVenture receives FDA clearance for OCD
Devices Neurology FDA
 HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 28 Oct 2019
Neuronetics(R) and Success TMS Partner to Increase Patient Access to Leading Depression Treatment, NeuroStar(R) Advanced Therapy
Devices Neurology
 HSMN NewsFeed - 1 Aug 2019
Neuronetics(R) Announces First TMS Patient Treated Under New Japan Reimbursement Policy
Devices Neurology Reimbursement
 HSMN NewsFeed - 29 Jul 2019
Neuronetics(R) Launches TrakStar(R) Plus Patient Data Management System to Maximize Physician Time with Patients
Devices Neurology Product Launch
 HSMN NewsFeed - 18 Jul 2019
Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of Directors
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 8 Jul 2019
NeuroStar(R) Patient Outcomes Registry Has Now Surpassed 3,000 Evaluable Patients, Making It The World's Largest in Major Depressive Disorder
Devices Neurology
 HSMN NewsFeed - 4 Apr 2019
Magstim TMS Receives FDA Clearance for 3- minute Theta Burst Treatment
Devices Neurology FDA
 HSMN NewsFeed - 20 Feb 2019
MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
Devices Neurology FDA
 HSMN NewsFeed - 22 Aug 2018
MagVenture, Inc: FDA Clears 3-Minute, Non-Pharmaceutical Depression Treatment
Devices Neurology FDA
 HSMN NewsFeed - 23 Jul 2018
Allergan Receives FDA Fast Track Designation for AGN-241751 for the Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2018
Flow Neuroscience Raises 1.1M USD in Seed Round Lead by Khosla Ventures to Develop a Device to Treat Depression
Devices Neurology Venture Capital
 HSMN NewsFeed - 17 Jan 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 27 Dec 2017
NeuroRx Signs Agreement With U.S. Dept. of Veterans Affairs and Baylor College of Medicine for Clinical Trial of First Drug Regimen Targeting Severe Bipolar Depression in Patients With Acute Suicidal Ideation & Behavior (ASIB)
Biopharmaceuticals Neurology
 HSMN NewsFeed - 10 Aug 2017
NeoSync Secures $13 Million in Financing with Valiance Life Science Investments and Current Investors
Devices Neurology Venture Capital
 HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Jun 2017
Magstim Group, Inc. Appoints Lothar Krinke as New CEO
Devices Neurology Personnel
 HSMN NewsFeed - 15 May 2017
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 12 Apr 2017
Roadblocks to Treatment for People Suffering from Depression Continue to be Lifted with Next Generation NeuroStar(R) Advanced Therapy
Devices Neurology Product Launch
 HSMN NewsFeed - 10 Mar 2017
Mylan Launches Generic Pristiq(R) Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 4 Nov 2016
The GeneSight(R) Precision Medicine Test Drives Significant Medication Cost Savings in Patients with Generalized Anxiety Disorder
Diagnostics Personalized Medicine
 HSMN NewsFeed - 5 Aug 2016
Allergan and Richter Provide Update on Cariprazine Program
Biopharmaceuticals
 HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Biopharmaceuticals Acquisitions Product Launch
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 20 May 2016
Neuralstem Announces Plan of Reorganization to Further Align Business with Strategic Intent
Regenerative Medicine Neurology
 HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 15 Mar 2016
Orexigen and Takeda Jointly Announce Orexigen's Acquisition of All Rights to CONTRAVE(R) in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 15 Mar 2016
Nuviant Medical Names Brian Blischak Chief Commercial Officer
Devices Neurology Personnel
 HSMN NewsFeed - 16 Feb 2016
Neuralstem Appoints Richard Daly as President and Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 29 Jan 2016
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Jan 2016
IntelGenx Strengthens Senior Management Team
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 23 Dec 2015
VistaGen Secures Exclusive Worldwide Commercial Rights to Three Proprietary Stem Cell Technologies from University Health Network
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 16 Nov 2015
NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD
Devices Neurology Regulatory
 HSMN NewsFeed - 9 Nov 2015
RedHill Biopharma and IntelGenx Announce First European Marketing Approval of RIZAPORT(TM) (RHB-103) for Migraines
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 28 Aug 2015
Therapy System for Treating Major Depressive Disorder Receives FDA Clearance
Devices Neurology FDA
 HSMN NewsFeed - 3 Aug 2015
Intra-Cellular Therapies Expands Leadership Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 13 Mar 2015
Minerva Neurosciences Announces $31 Million Financing
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 3 Dec 2014
Tal Medical Appoints Atul Pande, M.D., Former SVP and Head of Neurosciences at GSK, as Chief Medical Officer, EVP and SAB member
Devices Neurology Personnel
 HSMN NewsFeed - 3 Dec 2014
Naurex Raises $80 Million in Series C Financing to Advance Novel NMDA Receptor Modulators in Depression and Other CNS Disorders
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Jul 2014
Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden
Devices Neurology
 HSMN NewsFeed - 3 Jun 2014
Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President
Devices Neurology Personnel
 HSMN NewsFeed - 28 Mar 2014
NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives
Devices Neurology Personnel
 HSMN NewsFeed - 25 Feb 2014
David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President
Devices Neurology Personnel
 HSMN NewsFeed - 11 Feb 2014
Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller
Devices Neurology Personnel
 HSMN NewsFeed - 27 Jan 2014
Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer
Devices Neurology Personnel
 HSMN NewsFeed - 14 Jan 2014
Neuralstem Appoints Catherine Angell Sohn To Board Of Directors
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 5 Sep 2013
Neuralstem To Raise $4 Million In Registered Direct Offering
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 20 Aug 2013
Par Pharmaceutical Receives Approval of sANDA for Bupropion Hydrochloride Extended-Release Tablets USP (XL), 300 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Jan 2013
Neuralstem Receives FDA Approval To Commence Spinal Cord Injury Trial
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 17 Dec 2012
Naurex Completes $38 Million Series B Financing
Biopharmaceuticals Neurology Venture Capital Personnel
 HSMN NewsFeed - 10 Aug 2012
Neuren Appoints Joseph Horrigan, M.D., as VP of Clinical Development and Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2012
Neuralstem Updates ALS Stem Cell Trial Progress; Emory University Institutional Review Board Approves Amendment
Biopharmaceuticals Regenerative Medicine Neurology
 HSMN NewsFeed - 4 Jun 2012
Neuronetics, Inc. Receives CE Mark Approval for NeuroStar TMS Therapy
Devices Neurology Regulatory
 HSMN NewsFeed - 14 May 2012
Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Mar 2012
AstraZeneca and Targacept Announce Remaining TC-5214 Phase 3 Efficacy Studies Do Not Meet Primary Endpoint, Regulatory Filing Will Not Be Pursued
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2011
Neuralstem Receives Notice of Patent Allowance for Spinal Cord Delivery Platform
Regenerative Medicine Neurology
 HSMN NewsFeed - 7 Sep 2011
St. Jude Medical Announces European Regulatory Approval of First Implanted Neurostimulation Device to Treat Chronic Migraine
Devices Regulatory
 HSMN NewsFeed - 12 Jul 2011
St. Jude Medical Announces FDA Clearance for Industry-First Neurostimulation Lead Delivery System for the Management of Chronic Pain
Devices FDA
 HSMN NewsFeed - 11 Jul 2011
St. Jude Medical Receives FDA Approval for Expansion of BROADEN Deep Brain Stimulation Study for Depression
Devices Neurology
 HSMN NewsFeed - 23 Jun 2011
St. Jude Medical Reveals Randomized Clinical Trial Data Demonstrating Benefit of Neuromodulation for Chronic Migraine
Devices Neurology
 HSMN NewsFeed - 23 May 2011
St. Jude Medical Announces Australian Market Launch for First-of-Its-Kind Neurostimulation Lead Delivery System for Chronic Pain
Devices
 HSMN NewsFeed - 16 May 2011
Neuronetics, Inc. Raises $30 Million in Series E Financing
Devices Neurology Venture Capital
 HSMN NewsFeed - 25 Apr 2011
NeuroSigma Provides Update on Trigeminal Nerve Stimulation (TNS) - the USB Port to the Brain
Devices Neurology
 HSMN NewsFeed - 3 Mar 2011
Targacept Announces Termination of Strategic Alliance Agreement with GlaxoSmithKline
Biopharmaceuticals
 HSMN NewsFeed - 25 Jan 2011
Angelini Labopharm Confirms Appointment of Mary Anne Heino as President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Nov 2010
Impax Laboratories Receives Tentative FDA Approval for Generic Cymbalta(R) Delayed-Release 20, 30 and 60 mg Capsules
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 Sep 2010
AstraZeneca UK Receives Positive Decision For Seroquel XL(R)[Black Triangle Drug] (Quetiapine Prolonged Release) as an Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Aug 2010
Euthymics Bioscience, Inc. Appoints Industry Veterans Dr. Pierre Trân, Joan Manthis and William Pappafotopoulos to Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2010
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
Biopharmaceuticals
 HSMN NewsFeed - 27 May 2010
St. Jude Medical Announces European Approval for Industry-First Neurostimulation Lead Delivery System for the Management of Chronic Pain
Devices Neurosurgery
 HSMN NewsFeed - 3 Feb 2010
Cymbalta(R) Significantly Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 8 Dec 2009
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2009
St. Jude Medical Acquires Intellectual Property and Non-Cash Assets of Northstar Neuroscience, Inc.
Devices Neurology Acquisitions
 HSMN NewsFeed - 2 Jun 2009
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 6 May 2009
GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
Biopharmaceuticals Asquisitions
 HSMN NewsFeed - 6 May 2009
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2009
Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States
Biopharmaceuticals
 HSMN NewsFeed - 7 Apr 2009
IntelGenx Corp. and Cary Pharmaceuticals File NDA for CPI-300 Antidepressant
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Mar 2009
Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2009
UT Southwestern Performs First Local Implant in Deep Brain Stimulation Study for Depression
Devices Neurosurgery Neurology
 HSMN NewsFeed - 30 Jan 2009
Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 31 Dec 2008
Labopharm Announces FDA Approval of Once-Daily RYZOLT(TM) (Tramadol HCL Extended Release Tablets) for Management of Moderate to Moderately Severe Chronic Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2008
Biovail Enters into Commercial Alliance for Aplenzin
Biopharmaceuticals Distribution
 HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Biopharmaceuticals
 HSMN NewsFeed - 18 Nov 2008
Impax Sued Based on Anda for Generic Cymbalta(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 17 Nov 2008
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 Oct 2008
CeNeRx BioPharma Completes $15 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Oct 2008
FDA Clears NeuroStar(R) TMS Therapy for the Treatment of Depression
Devices Neurology FDA
 HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Biopharmaceuticals
 HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jun 2008
St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
Devices Neurology
 HSMN NewsFeed - 16 Jun 2008
Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 16 Jun 2008
FDA Approves Cymbalta(R) for the Management of Fibromyalgia
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jun 2008
Ambien CR(R) (zolpidem tartrate extended-release) CIV Tablets Improved Insomnia and Daily Functioning in Patients with Co-Morbid Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 3 Jun 2008
Northstar Neuroscience Announces Presentation of Long-Term Data of Cortical Stimulation for Depression and Stroke Recovery
Devices Neurosurgery
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 May 2008
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2008
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2008
Myriad Genetics Selects Lundbeck as European Partner for Flurizan
Biopharmaceuticals Neurology
 HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Biopharmaceuticals
 HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 May 2008
Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals
 HSMN NewsFeed - 21 Apr 2008
St. Jude Medical Awarded U.S. Patent for Neurostimulation Therapy for Depression
Devices Neurology
 HSMN NewsFeed - 28 Mar 2008
Actavis Receives Approval of Generic Wellbutrin SR(R) and Zyban(R) Tablets in the U.S.
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 19 Mar 2008
Forest Laboratories Announces Resignation of Ivan Gergel, MD
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2008
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2008
More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2008
Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
Biopharmaceuticals
 HSMN NewsFeed - 7 Feb 2008
St. Jude Medical Announces Clinical Study of Deep Brain Stimulation for Depression
Devices Neurology
 HSMN NewsFeed - 22 Jan 2008
Novexel and Forest Laboratories Announce License Agreement for NXL 104, a Novel Broad-Spectrum Beta Lactamase Inhibitor
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Jan 2008
In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2008
Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States
Biopharmaceuticals
 HSMN NewsFeed - 31 Dec 2007
Forest and Cypress Announce Submission of New Drug Application for Milnacipran for the Treatment of Fibromyalgia Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Dec 2007
Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2007
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
Biopharmaceuticals
 HSMN NewsFeed - 2 Dec 2007
FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Nov 2007
Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Nov 2007
Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2007
CeNeRx BioPharma Adds Dr. Daniel Burch as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2007
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 4 Sep 2007
Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2007
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR(TM)
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jul 2007
Wyeth Receives Approvable Letter from FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated with Menopause
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 26 Jun 2007
Barr Announces Tentative Approval for a Generic Version of Effexor(R) Tablets, 25mg, 37.5mg, 50mg, 75mg and 100mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 4 Jun 2007
Barr and Eli Lilly Voluntarily Dismiss Patent Litigation on Prozac(R) Weekly(TM)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 31 May 2007
Topline Results of Phase III Study in Acute Ischemic Stroke (Dias-2) Do Not Demonstrate Difference Between Desmoteplase and Placebo
Biopharmaceuticals Neurology
 HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
BENICAR HCT(R) Reductions in Seated Systolic Blood Pressure for Stage 2 Patients Compared With Amlodipine + Benazepril
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 21 May 2007
Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2007
Response Submitted to FDA Approvable Letter for Hypertension Compound Nebivolol
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 2 Apr 2007
EPIX Provides Update Regarding Status of Vasovist(TM) Appeal
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 26 Feb 2007
FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Feb 2007
Sepracor Announces Publication of Additional Data from Lunesta(R) Insomnia-Depression Study in the Journal of Clinical Sleep Medicine
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2007
Ranbaxy Gains Final Approval for Sertraline Hydrochloride Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 6 Feb 2007
Barr's Subsidiary PLIVA Receives Final Approval for Generic ZOLOFT(R) Tablets, 25 mg, 50 mg and 100 mg
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jan 2007
Wyeth Receives Approvable Letter From FDA for Pristiq (Desvenlafaxine Succinate) for the Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2007
Forest Laboratories Announces Completion of Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2007
Lupin Pharmaceuticals Announces Tentative Approval of Generic ZOLOFT(R)
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Dec 2006
Cerexa to Be Acquired by Forest Laboratories for $480 Million Plus Potential $100 Million Milestone Payment
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Dec 2006
Forest Laboratories Announces Acquisition of Cerexa, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2006
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2006
Patient Recruitment to Resume Without Modification of Protocol for Desmoteplase Phase IIB/III Stroke Study DIAS-2
Biopharmaceuticals Neurology
 HSMN NewsFeed - 23 Oct 2006
U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Oct 2006
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Sep 2006
Forest Laboratories Inc. Announces Appointment of Dr. Lawrence S. Olanoff as President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2006
Forest Announces Federal Court Upholds Lexapro(R) Patent
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 30 Jun 2006
Teva Receives FDA Approval for Generic Zoloft(R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 23 Jun 2006
Sepracor Announces Presentation of LUNESTA(TM) Data at Associated Professional Sleep Societies 20th Anniversary Meeting
Biopharmaceuticals
 HSMN NewsFeed - 25 May 2006
Desvenlafaxine Succinate (DVS-233) Phase 3 Data Show Significant Improvement in Symptoms of Depression in Adult Patients Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Reports Venlafaxine Extended Release May Help Adult Patients Prevent New Episodes of Depression for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
Aspect Antidepressant Response Index Accurately Predicts Patient Response to SSRI's after One Week on Medication
Devices
 HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2006
Barr Challenging Patents Protecting Prozac(R) Weekly(TM)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 118

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 118 additional stories matching:
major depressive disorder
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.